ReferenceID 6277
Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes
Am J Physiol Cell Physiol
Cancer cachexia is common in many cancers and the loss of skeletal muscle mass compromises the response to therapies and quality of life. A contributing mechanism is oxidative stress and compounds able to attenuate it ma
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 6277
- Evidence Id
- 22867
- Core Evidence Id
- 22867
- Source Reference Id
- 5832
- Herb2 Reference Id
- HBREF006629
- Subject Paper Key
- HBIN045135_36534500
- Pubmed Id
- 36534500
- Doi
- 10.1152/ajpcell.00025.2022
- Paper Title
- Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes
- Paper Abstract
- Cancer cachexia is common in many cancers and the loss of skeletal muscle mass compromises the response to therapies and quality of life. A contributing mechanism is oxidative stress and compounds able to attenuate it may be protective. Sulforaphane (SFN), a natural antioxidant in cruciferous vegetables, activates nuclear factor erythroid 2-related factor 2 (Nrf2) signaling to decrease oxidative stress. Although SFN has potential as a cancer therapeutic, whether it can attenuate muscle wasting in the absence or presence of chemotherapy is unknown. In healthy C2C12 myotubes, SFN administration for 48 h induced hypertrophy through increased myoblast fusion via Nrf2 and ERK signaling. To determine whether SFN could attenuate wasting induced by cancer cells, myotubes were cocultured with or without Colon-26 (C-26) cancer cells for 48 h and treated with 5-fluorouracil (5-FU, 5 µM) or vehicle (DMSO). SFN (10 µM) or DMSO was added for the final 24 h. Coculture with cancer cells in the absence and presence of 5-FU reduced myotube width by ∼30% ( P < 0.001) and ∼20% ( P < 0.01), respectively, which was attenuated by SFN ( P < 0.05). Exposure to C-26 conditioned media reduced myotube width by 15% ( P < 0.001), which was attenuated by SFN. Western immunoblotting and qRT-PCR confirmed activation of Nrf2 signaling and antioxidant genes. Coadministration of Nrf2 inhibitors (ML-385) or MEK inhibitors (PD184352) revealed that SFN's attenuation of atrophy was blocked by ERK inhibition. These data support the chemoprotective and antioxidative function of SFN in myotubes, highlighting its therapeutic potential for cancer-related muscle wasting.
- Journal
- Am J Physiol Cell Physiol
- Publish Year
- 2022
- Experiment Subject
- Experiment Type
- Cell Experiment
- Phenotype Related
- Cancer Cachexia; Wasting; Cancers; Muscle Wasting; Cancer-related Muscle Wasting; Cancer
- Paper Title Cn
- Paper Title En
- Sulforaphane attenuates cancer cell-induced atrophy of C2C12 myotubes
- Bilingual Status
- semi_complete